Pasithea Therapeutics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Pasithea Therapeutics Corp. on September 9, 2026. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbols KTTA (Common Stock) and KTTAW (Warrants). The filing details the voting results for three specific proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting outcomes rather than financial performance data.
Material Changes and Voting Results
Of the 33,414,448 shares outstanding, 26,142,328 shares were represented at the meeting, constituting a quorum. The following material actions were approved:
- Director Elections: Two Class III directors were elected for a three-year term expiring in 2029. Dr. Tiago Reis Marques received 18,381,039 votes FOR, and Prof. Lawrence Steinman received 17,000,205 votes FOR.
- Auditor Ratification: Shareholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,935,574 votes FOR.
- Reverse Stock Split Authorization: Shareholders approved an amendment to the Certificate of Incorporation authorizing the Board to effect a reverse stock split at a ratio between 1:2 and 1:20. This authorization is valid for one year from the meeting date, with the specific ratio to be determined by the Board without further shareholder approval.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, or specific risk factors beyond the authorization of the reverse stock split. The approval of the reverse stock split indicates a strategic move to adjust the share structure, potentially to meet listing requirements or improve market perception, though the exact timing and ratio remain at the Board's discretion.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and implementation date once announced by the Board, as the filing only authorizes a range of 1:2 to 1:20.
- Confirm the impact of the reverse stock split on the number of shares held and the adjusted share price.
- Review the upcoming 10-K filing for the fiscal year ending December 31, 2026, to obtain the financial metrics absent from this 8-K.
- Note the significant number of broker non-votes (7,693,895) on the director election proposals, indicating a large portion of shares held in street name did not receive voting instructions.